Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.

The feasibility of exploiting secretory phospholipase A2 (sPLA2) enzymes, which are overexpressed in tumors, to activate drug release from liposomes precisely at the tumor site has been demonstrated before. Although the efficacy of the developed formulations was evaluated using in vitro and in vivo...

Full description

Bibliographic Details
Main Authors: Ahmad Arouri, Jakub Trojnar, Steffen Schmidt, Anders H Hansen, Jan Mollenhauer, Ole G Mouritsen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4422686?pdf=render
id doaj-58e44ff3ee4f4e60a31d49dadfea6c48
record_format Article
spelling doaj-58e44ff3ee4f4e60a31d49dadfea6c482020-11-24T22:12:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01105e012550810.1371/journal.pone.0125508Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.Ahmad ArouriJakub TrojnarSteffen SchmidtAnders H HansenJan MollenhauerOle G MouritsenThe feasibility of exploiting secretory phospholipase A2 (sPLA2) enzymes, which are overexpressed in tumors, to activate drug release from liposomes precisely at the tumor site has been demonstrated before. Although the efficacy of the developed formulations was evaluated using in vitro and in vivo models, the pattern of sPLA2-assisted drug release is unknown due to the lack of a suitable bio-relevant model. We report here on the development of a novel bioluminescence living-cell-based luciferase assay for the monitoring of sPLA2-triggered release of luciferin from liposomes. To this end, we engineered breast cancer cells to produce both luciferase and sPLA2 enzymes, where the latter is secreted to the extracellular medium. We report on setting up a robust and reproducible bioassay for testing sPLA2-sensitive, luciferin remote-loaded liposomal formulations, using 1,2-distearoyl-sn-glycero-3-phosphatidylcholine/1,2-distearoyl-sn-glycero-3-phosphatidylglycerol (DSPC/DSPG) 7:3 and DSPC/DSPG/cholesterol 4:3:3 as initial test systems. Upon their addition to the cells, the liposomes were degraded almost instantaneously by sPLA2 releasing the encapsulated luciferin, which provided readout from the luciferase-expressing cells. Cholesterol enhanced the integrity of the formulation without affecting its susceptibility to sPLA2. PEGylation of the liposomes only moderately broadened the release profile of luciferin. The provided bioassay represents a useful tool for monitoring active drug release in situ in real time as well as for testing and optimizing of sPLA2-sensitive lipid formulations. In addition, the bioassay will pave the way for future in-depth in vitro and in vivo studies.http://europepmc.org/articles/PMC4422686?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Ahmad Arouri
Jakub Trojnar
Steffen Schmidt
Anders H Hansen
Jan Mollenhauer
Ole G Mouritsen
spellingShingle Ahmad Arouri
Jakub Trojnar
Steffen Schmidt
Anders H Hansen
Jan Mollenhauer
Ole G Mouritsen
Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
PLoS ONE
author_facet Ahmad Arouri
Jakub Trojnar
Steffen Schmidt
Anders H Hansen
Jan Mollenhauer
Ole G Mouritsen
author_sort Ahmad Arouri
title Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
title_short Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
title_full Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
title_fullStr Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
title_full_unstemmed Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.
title_sort development of a cell-based bioassay for phospholipase a2-triggered liposomal drug release.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description The feasibility of exploiting secretory phospholipase A2 (sPLA2) enzymes, which are overexpressed in tumors, to activate drug release from liposomes precisely at the tumor site has been demonstrated before. Although the efficacy of the developed formulations was evaluated using in vitro and in vivo models, the pattern of sPLA2-assisted drug release is unknown due to the lack of a suitable bio-relevant model. We report here on the development of a novel bioluminescence living-cell-based luciferase assay for the monitoring of sPLA2-triggered release of luciferin from liposomes. To this end, we engineered breast cancer cells to produce both luciferase and sPLA2 enzymes, where the latter is secreted to the extracellular medium. We report on setting up a robust and reproducible bioassay for testing sPLA2-sensitive, luciferin remote-loaded liposomal formulations, using 1,2-distearoyl-sn-glycero-3-phosphatidylcholine/1,2-distearoyl-sn-glycero-3-phosphatidylglycerol (DSPC/DSPG) 7:3 and DSPC/DSPG/cholesterol 4:3:3 as initial test systems. Upon their addition to the cells, the liposomes were degraded almost instantaneously by sPLA2 releasing the encapsulated luciferin, which provided readout from the luciferase-expressing cells. Cholesterol enhanced the integrity of the formulation without affecting its susceptibility to sPLA2. PEGylation of the liposomes only moderately broadened the release profile of luciferin. The provided bioassay represents a useful tool for monitoring active drug release in situ in real time as well as for testing and optimizing of sPLA2-sensitive lipid formulations. In addition, the bioassay will pave the way for future in-depth in vitro and in vivo studies.
url http://europepmc.org/articles/PMC4422686?pdf=render
work_keys_str_mv AT ahmadarouri developmentofacellbasedbioassayforphospholipasea2triggeredliposomaldrugrelease
AT jakubtrojnar developmentofacellbasedbioassayforphospholipasea2triggeredliposomaldrugrelease
AT steffenschmidt developmentofacellbasedbioassayforphospholipasea2triggeredliposomaldrugrelease
AT andershhansen developmentofacellbasedbioassayforphospholipasea2triggeredliposomaldrugrelease
AT janmollenhauer developmentofacellbasedbioassayforphospholipasea2triggeredliposomaldrugrelease
AT olegmouritsen developmentofacellbasedbioassayforphospholipasea2triggeredliposomaldrugrelease
_version_ 1725803423772704768